Developer docs
API playgroundTry for free, no card

Search company profiles

roxi-ai

Full company profile

uuid02ml718

Namestring
roxi-ai
Legal namestring
Roxi-AI
Websiteurl
roxi-ai.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Roxi-AI is a life sciences analytics company founded in 2024 and based in Yardley, United States, providing predictive risk analysis and research tools for biopharma asset evaluation and investment diligence. Its buyers are biopharma R&D, business development, medical and commercial teams; investment funds and research analysts (hedge funds, crossover funds, VC/PE, sell-side analysts); clinical development service providers (CROs); and investors and strategic partners. The company presents a two-person leadership team, Deepak Patil, MBBS, MBA, MS (Founder) and Lorraine Marchand, MBA (Partner/Contact), with no total headcount, incorporation details or funding disclosed.

The core technology is a longitudinal, outcomes-linked risk signal platform. A knowledge graph unifies fragmented clinical, scientific, regulatory and market evidence, time-stamps it and maps it to each asset's development path, feeding explainable predictive models trained and validated against historical approvals, halts and regulatory guidance. The proprietary ROXI 100 / Roxi-100 framework codifies 900+ weighted, time-stamped risk signals linked to outcomes and underpins ROXI INDEX (AAA-D graded asset risk assessment), BENCHMARK PRO (peer and industry benchmarking), SIMULATOR (scenario and portfolio stress testing), ASK ROXI (an AI research/diligence agent returning cited, explainable answers with governance controls) and ROXI CONNECT (a biopharma deal marketplace). Delivery is a hybrid of product and services: 72-hour diligence sprints ending in an investor-committee-ready memo, on-demand ticker/asset risk readouts, portfolio diagnostic and benchmarking engagements, and a competitive and catalyst radar, alongside advisory practices covering real world data strategy, R&D strategy, medical affairs, launch and commercial, and innovation acceleration. The company claims 92% directional accuracy at Phase-1 start on a blinded retrospective oncology cohort (n=64), with methods and limitations available only on request.

The business model spans four monetisation routes: authenticated platform and data subscription access through the web application at app.roxi-ai.com; professional services delivered as engagements (diligence sprints, equity research readouts, portfolio diagnostics); data monetisation of the ROXI 100, ROXI INDEX, BENCHMARK PRO and SIMULATOR modules; and marketplace economics on ROXI CONNECT matches. Go-to-market is demo-led and consultative, with calls to action to evaluate a company, assess a ticker, benchmark a portfolio or schedule a demo feeding an inquiry form segmented into Pharma & Biotech, Funds & Analysts, and Investors & Partners, supplemented by self-serve app access and website content demand generation tracked via Google Analytics. Pricing is quote-based and not publicly disclosed, and no revenue, ARR, funding, customer roster, incorporation details, patents or geographic footprint are disclosed in the source material.

Short descriptiontext

Roxi-AI is a life sciences analytics startup providing predictive, outcome-linked risk intelligence for biopharma asset evaluation and investment diligence, delivered via the ROXI 100 platform, ASK ROXI agent, diligence sprints and ROXI CONNECT marketplace to pharma, biotech, funds and analysts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersYardley, United States
HQ citystring
Yardley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biopharma risk intelligence, investment diligence analytics, clinical trial outcome prediction, life sciences knowledge graph, portfolio risk benchmarking
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGALAD
Risk Management & Benefit–Risk (RMP/REMS/PSUR-PBRER)
SECONDARYBPAHAFAH
Risk Quantification, Modeling & Stress Testing
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Other Scientific and Technical Consulting Services54169
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Investment Advice6282
Product category
Life Sciences Risk Intelligence Analytics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Platform/data subscription access
TypeSubscription Recurring
Description

Authenticated access to the Roxi-AI web application and risk signal database (app.roxi-ai.com), implying a recurring subscription/paid-access model for the risk intelligence platform. Pricing is not publicly disclosed.

app.roxi-ai.com
2Diligence sprints and professional advisory services
TypeProfessional Services
Description

72-hour focused diligence sprints on a company or asset, on-demand ticker/asset risk readouts with equity research reports, and portfolio diagnostic & benchmarking engagements delivered as engagements with IC-ready memos (project/service-based, one-time or repeat engagements).

roxi-ai.com
3ROXI CONNECT marketplace
TypeMarketplace Commission
Description

Biopharma deal marketplace connecting biopharma companies with investors; revenue likely transaction- or commission-based on matched deals, though no commercial terms are disclosed.

roxi-ai.com
4Outcome-linked risk data and benchmarking products
TypeData Monetisation
Description

Monetisation of the proprietary longitudinal, outcome-linked risk signals database and ROXI 100 / ROXI INDEX / BENCHMARK PRO / SIMULATOR tools (data monetisation), sold to funds, analysts and biopharma teams.

roxi-ai.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1ROXI 100
Description

Proprietary 100-point risk benchmarking system used to evaluate biopharma assets and surface opportunities for de-risking development plans; also referenced as the 'Roxi-100' framework codifying 900+ weighted, time-stamped risk signals linked to outcomes.

roxi-ai.com
+5 more records
Core offering1 text field

Roxi-AI builds a longitudinal, outcomes-linked risk signals platform for biopharma: a knowledge graph that normalizes and time-stamps trial, regulatory, mechanistic, safety, competitive and commercial evidence, maps it to each asset's development path, and feeds explainable predictive models trained and validated against historical approvals, halts and regulatory guidance. The proprietary ROXI 100 framework codifies 900+ weighted, time-stamped risk signals linked to real outcomes, exposed through ROXI INDEX (AAA-D graded risk assessment), BENCHMARK PRO, SIMULATOR and the ASK ROXI AI research agent, and delivered as 72-hour diligence sprints, on-demand ticker/asset readouts, portfolio diagnostics, competitive/catalyst radar and advisory services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 92% directional accuracy at Phase-1 start on a blinded retrospective oncology cohort (n=64), with clear early separation between eventual approvals and failures
+2 more records
Product overview1 text field

Roxi-AI is a platform-plus-modules offering rather than a single unified product: a proprietary longitudinal, outcomes-linked risk signals data foundation and knowledge graph of time-stamped clinical, regulatory, mechanistic, safety, competitive and commercial evidence underpins the core proprietary ROXI 100 100-point risk benchmarking framework, which in turn powers the ROXI INDEX (AAA-D graded asset risk assessment), BENCHMARK PRO (peer/industry benchmarking), SIMULATOR (scenario and portfolio stress testing) and ASK ROXI (AI diligence/research agent), alongside the ROXI CONNECT biopharma deal marketplace. These modules are delivered to funds, analysts and biopharma teams through service offerings — Diligence Sprint, Ticker/Asset Risk Readout, Portfolio Diagnostic & Benchmarking and Competitive & Catalyst Radar — and complementary advisory practices (Real World Data Strategy, R&D Strategy, Medical Affairs, Launch & Commercial, Innovation Acceleration).

Product and service15 records
1ROXI 100
CategoryCore product / proprietary risk framework
Description

Proprietary 100-point risk benchmarking system for biopharma assets and companies, built on 900+ weighted, time-stamped risk signals linked to real clinical and regulatory outcomes; used to evaluate assets and surface opportunities for de-risking development plans.

2ROXI INDEX
CategoryCore product / assessment engine
Description

Predictive assessment engine that rigorously evaluates biopharma assets using a comprehensive risk assessment graded on an AAA-D scale.

3BENCHMARK PRO
CategoryProduct module / peer benchmarking
Description

Compares the risk profiles of biopharma assets against industry and peer benchmarks, supporting like-for-like competitive and peer profiling.

4SIMULATOR
CategoryProduct module / scenario modeling
Description

Simulates the impact of strategic design considerations and portfolio scenarios on the likelihood of clinical, regulatory and market success of an asset, used for portfolio and scenario stress tests.

5ASK ROXI (AI research agent)
CategoryProduct module / AI research agent
Description

AI research copilot and diligence agent trained on life-sciences data, workflows and Roxi-AI risk signals; performs deep multi-step searches and returns cited, explainable answers with governance controls for R&D, medical and commercial teams and fund analysts.

6ROXI CONNECT
CategoryMarketplace platform
Description

Biopharma deal marketplace facilitating connections between biopharma companies and investors, used for deal sourcing and introductions.

7Diligence Sprint
CategoryService offering
Description

A 72-hour focused, explainable review of a company or asset using outcome-linked risk signals, finished with an investor-committee-ready memo; aimed at funds, analysts and biopharma teams making diligence decisions.

8Ticker / Asset Risk Readout
CategoryService offering
Description

On-demand signal snapshot with asset-level risk summaries, key drivers and peer comparators, built for public-market investment decisions; includes downloadable equity research reports and asset risk summaries for funds and analysts.

9Portfolio Diagnostic & Benchmarking
CategoryService offering
Description

Maps risks across a pipeline or portfolio, identifies fixable issues and benchmarks against peers to prioritise capital and work, with portfolio roll-ups of risk drivers and expected impact.

10Competitive & Catalyst Radar
CategoryService offering
Description

Continuous tracking of peer assets, milestones and risk shifts so teams identify inflection points before the market or the deal table, with near real-time updates as new evidence emerges.

11Real World Data Strategy
CategoryAdvisory service
Description

Advisory service that unlocks value across disconnected in-house and third-party real world data sets for biopharma clients.

12R&D Strategy
CategoryAdvisory service
Description

Advisory service focused on pipeline optimization and organisation-wide synergy enablement for early stage assets.

13Medical Affairs
CategoryAdvisory service
Description

Medical affairs enablement advisory service that prepares the market for successful product launches.

14Launch & Commercial
CategoryAdvisory service
Description

Advisory service covering pricing, go-to-market strategy and predictive market risk mitigation for biopharma launches.

15Innovation Acceleration
CategoryAdvisory service
Description

Advisory service applying patient- and HCP-centric innovation models to drive cross-functional innovation.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1NVIDIA (NVIDIA Inception Program)
Strategic tierMinorTypeOthers
Description

Roxi-AI is a member of the NVIDIA Inception Program, an accelerator for AI startups. The membership is displayed in the company's 'Programs & ecosystem' section on the Company page. It supports the company's AI-model and compute build-out for its biopharma risk intelligence platform. No specific deliverables, funding amount or dates are disclosed.

roxi-ai.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Trilytics
TypeDirect peer
Description

Applies machine learning to drug and device programs to estimate probability of technical success and inform pipeline prioritisation — the closest analog to Roxi-AI's ROXI INDEX graded asset-risk assessment and predictive success models.

2Citeline
TypeDirect peer
Description

Provides pharma R&D intelligence, clinical trial and pipeline data analytics used by biotech, pharma and investors for asset evaluation and competitive benchmarking, directly overlapping Roxi-AI's signal database and benchmarking products.

3Evaluate Pharma
TypeDirect peer
Description

Aggregates clinical, commercial and financial data into consensus forecasts and R&D risk/opportunity analysis for pipelines, serving the same biopharma BD and investor decision use cases as ROXI 100 and BENCHMARK PRO.

4BioWorld
TypeDirect peer
Description

Business intelligence on biotech pipelines, clinical trials, deals and company profiles with news, data and analysis; competes for the same budget and workflow in biopharma asset evaluation and investor diligence.

5AlphaSense
TypeDirect peer
Description

AI-driven market intelligence and diligence platform used by investment teams to research and answer questions with citations — the closest analog to ASK ROXI and to Roxi-AI's Funds & Analysts segment offering.

6DealForma
TypeDirect peer
Description

Pharma pipeline and market intelligence platform built for business development teams to evaluate and de-risk pipeline and licensing opportunities, overlapping Roxi-AI's use case of prioritising which assets to keep, kill or remediate.

7Consensus
TypeEmerging player
Description

AI research platform that surfaces cited answers from primary research for analysts and investors; comparable in model (AI copilot over research corpus) though it is not specialised to biopharma asset risk.

8BioCentury
TypeDirect peer
Description

Biotech strategy intelligence, pipeline data and analyst reports aimed at biotech executives and investors, competing for the same decision-support spend as Roxi-AI's equity research reports and diligence sprints.

9Certara
TypeBroad incumbent
Description

Provides quantitative biosimulation and R&D portfolio strategy software to pharma, with a broader scientific modelling portfolio that overlaps Roxi-AI's SIMULATOR scenario modelling for likelihood of success.

10IQVIA
TypeBroad incumbent
Description

Large-scale R&D and commercial data, analytics and advisory franchise spanning clinical data, real-world evidence and trial analytics; a broad incumbent whose data assets and client base overlap Roxi-AI's biopharma risk intelligence market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

roxi-ai

Life Sciences Risk Intelligence Analyticsroxi-ai.com

Roxi-AI is a life sciences analytics startup providing predictive, outcome-linked risk intelligence for biopharma asset evaluation and investment diligence, delivered via the ROXI 100 platform, ASK ROXI agent, diligence sprints and ROXI CONNECT marketplace to pharma, biotech, funds and analysts.

What roxi-ai does

Roxi-AI is a life sciences analytics company founded in 2024 and based in Yardley, United States, providing predictive risk analysis and research tools for biopharma asset evaluation and investment diligence. Its buyers are biopharma R&D, business development, medical and commercial teams; investment funds and research analysts (hedge funds, crossover funds, VC/PE, sell-side analysts); clinical development service providers (CROs); and investors and strategic partners. The company presents a two-person leadership team, Deepak Patil, MBBS, MBA, MS (Founder) and Lorraine Marchand, MBA (Partner/Contact), with no total headcount, incorporation details or funding disclosed.

The core technology is a longitudinal, outcomes-linked risk signal platform. A knowledge graph unifies fragmented clinical, scientific, regulatory and market evidence, time-stamps it and maps it to each asset's development path, feeding explainable predictive models trained and validated against historical approvals, halts and regulatory guidance. The proprietary ROXI 100 / Roxi-100 framework codifies 900+ weighted, time-stamped risk signals linked to outcomes and underpins ROXI INDEX (AAA-D graded asset risk assessment), BENCHMARK PRO (peer and industry benchmarking), SIMULATOR (scenario and portfolio stress testing), ASK ROXI (an AI research/diligence agent returning cited, explainable answers with governance controls) and ROXI CONNECT (a biopharma deal marketplace). Delivery is a hybrid of product and services: 72-hour diligence sprints ending in an investor-committee-ready memo, on-demand ticker/asset risk readouts, portfolio diagnostic and benchmarking engagements, and a competitive and catalyst radar, alongside advisory practices covering real world data strategy, R&D strategy, medical affairs, launch and commercial, and innovation acceleration. The company claims 92% directional accuracy at Phase-1 start on a blinded retrospective oncology cohort (n=64), with methods and limitations available only on request.

The business model spans four monetisation routes: authenticated platform and data subscription access through the web application at app.roxi-ai.com; professional services delivered as engagements (diligence sprints, equity research readouts, portfolio diagnostics); data monetisation of the ROXI 100, ROXI INDEX, BENCHMARK PRO and SIMULATOR modules; and marketplace economics on ROXI CONNECT matches. Go-to-market is demo-led and consultative, with calls to action to evaluate a company, assess a ticker, benchmark a portfolio or schedule a demo feeding an inquiry form segmented into Pharma & Biotech, Funds & Analysts, and Investors & Partners, supplemented by self-serve app access and website content demand generation tracked via Google Analytics. Pricing is quote-based and not publicly disclosed, and no revenue, ARR, funding, customer roster, incorporation details, patents or geographic footprint are disclosed in the source material.

roxi-ai firmographics

Firmographics
Name
roxi-ai
Legal name
Roxi-AI
Website
https://roxi-ai.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Roxi-AI is a life sciences analytics startup providing predictive, outcome-linked risk intelligence for biopharma asset evaluation and investment diligence, delivered via the ROXI 100 platform, ASK ROXI agent, diligence sprints and ROXI CONNECT marketplace to pharma, biotech, funds and analysts.
Ownership category
akta.pro rank

roxi-ai industry classification

Industry
Product category
Life Sciences Risk Intelligence Analytics
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Commercial Physical & Biological Research (8731), Investment Advice (6282)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGALAD
Risk Management & Benefit–Risk (RMP/REMS/PSUR-PBRER)
SECONDARYBPAHAFAH
Risk Quantification, Modeling & Stress Testing

Keywords

  • Biopharma risk intelligence
  • Investment diligence analytics
  • Clinical trial outcome prediction
  • Life sciences knowledge graph
  • Portfolio risk benchmarking

Where roxi-ai is headquartered

Location

Headquarters

HQ city
Yardley
HQ country
United States
HQ region
North America

Markets served

roxi-ai business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Platform/data subscription access: Authenticated access to the Roxi-AI web application and risk signal database (app.roxi-ai.com), implying a recurring subscription/paid-access model for the risk intelligence platform. Pricing is not publicly disclosed.
  2. Diligence sprints and professional advisory services: 72-hour focused diligence sprints on a company or asset, on-demand ticker/asset risk readouts with equity research reports, and portfolio diagnostic & benchmarking engagements delivered as engagements with IC-ready memos (project/service-based, one-time or repeat engagements).
  3. ROXI CONNECT marketplace: Biopharma deal marketplace connecting biopharma companies with investors; revenue likely transaction- or commission-based on matched deals, though no commercial terms are disclosed.
  4. Outcome-linked risk data and benchmarking products: Monetisation of the proprietary longitudinal, outcome-linked risk signals database and ROXI 100 / ROXI INDEX / BENCHMARK PRO / SIMULATOR tools (data monetisation), sold to funds, analysts and biopharma teams.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels3 records

roxi-ai product offering

Product offering

Core offering

Roxi-AI builds a longitudinal, outcomes-linked risk signals platform for biopharma: a knowledge graph that normalizes and time-stamps trial, regulatory, mechanistic, safety, competitive and commercial evidence, maps it to each asset's development path, and feeds explainable predictive models trained and validated against historical approvals, halts and regulatory guidance. The proprietary ROXI 100 framework codifies 900+ weighted, time-stamped risk signals linked to real outcomes, exposed through ROXI INDEX (AAA-D graded risk assessment), BENCHMARK PRO, SIMULATOR and the ASK ROXI AI research agent, and delivered as 72-hour diligence sprints, on-demand ticker/asset readouts, portfolio diagnostics, competitive/catalyst radar and advisory services.

Product overview

Roxi-AI is a platform-plus-modules offering rather than a single unified product: a proprietary longitudinal, outcomes-linked risk signals data foundation and knowledge graph of time-stamped clinical, regulatory, mechanistic, safety, competitive and commercial evidence underpins the core proprietary ROXI 100 100-point risk benchmarking framework, which in turn powers the ROXI INDEX (AAA-D graded asset risk assessment), BENCHMARK PRO (peer/industry benchmarking), SIMULATOR (scenario and portfolio stress testing) and ASK ROXI (AI diligence/research agent), alongside the ROXI CONNECT biopharma deal marketplace. These modules are delivered to funds, analysts and biopharma teams through service offerings — Diligence Sprint, Ticker/Asset Risk Readout, Portfolio Diagnostic & Benchmarking and Competitive & Catalyst Radar — and complementary advisory practices (Real World Data Strategy, R&D Strategy, Medical Affairs, Launch & Commercial, Innovation Acceleration).

Differentiator

Problem solved

Functional benefit

Brands

  • ROXI 100: Proprietary 100-point risk benchmarking system used to evaluate biopharma assets and surface opportunities for de-risking development plans; also referenced as the 'Roxi-100' framework codifying 900+ weighted, time-stamped risk signals linked to outcomes.
  • ROXI INDEX
  • BENCHMARK PRO
  • SIMULATOR
  • ASK ROXI
  • ROXI CONNECT

Products and services

  • ROXI 100 Proprietary 100-point risk benchmarking system for biopharma assets and companies, built on 900+ weighted, time-stamped risk signals linked to real clinical and regulatory outcomes; used to evaluate assets and surface opportunities for de-risking development plans.
  • ROXI INDEX Predictive assessment engine that rigorously evaluates biopharma assets using a comprehensive risk assessment graded on an AAA-D scale.
  • BENCHMARK PRO Compares the risk profiles of biopharma assets against industry and peer benchmarks, supporting like-for-like competitive and peer profiling.
  • SIMULATOR Simulates the impact of strategic design considerations and portfolio scenarios on the likelihood of clinical, regulatory and market success of an asset, used for portfolio and scenario stress tests.
  • ASK ROXI (AI research agent) AI research copilot and diligence agent trained on life-sciences data, workflows and Roxi-AI risk signals; performs deep multi-step searches and returns cited, explainable answers with governance controls for R&D, medical and commercial teams and fund analysts.
  • ROXI CONNECT Biopharma deal marketplace facilitating connections between biopharma companies and investors, used for deal sourcing and introductions.
  • Diligence Sprint A 72-hour focused, explainable review of a company or asset using outcome-linked risk signals, finished with an investor-committee-ready memo; aimed at funds, analysts and biopharma teams making diligence decisions.
  • Ticker / Asset Risk Readout On-demand signal snapshot with asset-level risk summaries, key drivers and peer comparators, built for public-market investment decisions; includes downloadable equity research reports and asset risk summaries for funds and analysts.
  • Portfolio Diagnostic & Benchmarking Maps risks across a pipeline or portfolio, identifies fixable issues and benchmarks against peers to prioritise capital and work, with portfolio roll-ups of risk drivers and expected impact.
  • Competitive & Catalyst Radar Continuous tracking of peer assets, milestones and risk shifts so teams identify inflection points before the market or the deal table, with near real-time updates as new evidence emerges.
  • Real World Data Strategy Advisory service that unlocks value across disconnected in-house and third-party real world data sets for biopharma clients.
  • R&D Strategy Advisory service focused on pipeline optimization and organisation-wide synergy enablement for early stage assets.
  • Medical Affairs Medical affairs enablement advisory service that prepares the market for successful product launches.
  • Launch & Commercial Advisory service covering pricing, go-to-market strategy and predictive market risk mitigation for biopharma launches.
  • Innovation Acceleration Advisory service applying patient- and HCP-centric innovation models to drive cross-functional innovation.

Quantifiable outcome

  • 92% directional accuracy at Phase-1 start on a blinded retrospective oncology cohort (n=64), with clear early separation between eventual approvals and failures
  • +2 more outcomes

Companies that use roxi-ai

Customer profile

Segments4 records

Ideal customer profiles4 records

roxi-ai technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature8 records

roxi-ai partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NVIDIA (NVIDIA Inception Program)minorOthersRoxi-AI is a member of the NVIDIA Inception Program, an accelerator for AI startups. The membership is displayed in the company's 'Programs & ecosystem' section on the Company page. It supports the company's AI-model and compute build-out for its biopharma risk intelligence platform. No specific deliverables, funding amount or dates are disclosed.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

roxi-ai competitors and assessment

Company assessment

Direct peers

  • Trilytics: Applies machine learning to drug and device programs to estimate probability of technical success and inform pipeline prioritisation — the closest analog to Roxi-AI's ROXI INDEX graded asset-risk assessment and predictive success models.
  • Citeline: Provides pharma R&D intelligence, clinical trial and pipeline data analytics used by biotech, pharma and investors for asset evaluation and competitive benchmarking, directly overlapping Roxi-AI's signal database and benchmarking products.
  • Evaluate Pharma: Aggregates clinical, commercial and financial data into consensus forecasts and R&D risk/opportunity analysis for pipelines, serving the same biopharma BD and investor decision use cases as ROXI 100 and BENCHMARK PRO.
  • BioWorld: Business intelligence on biotech pipelines, clinical trials, deals and company profiles with news, data and analysis; competes for the same budget and workflow in biopharma asset evaluation and investor diligence.
  • AlphaSense: AI-driven market intelligence and diligence platform used by investment teams to research and answer questions with citations — the closest analog to ASK ROXI and to Roxi-AI's Funds & Analysts segment offering.
  • DealForma: Pharma pipeline and market intelligence platform built for business development teams to evaluate and de-risk pipeline and licensing opportunities, overlapping Roxi-AI's use case of prioritising which assets to keep, kill or remediate.
  • BioCentury: Biotech strategy intelligence, pipeline data and analyst reports aimed at biotech executives and investors, competing for the same decision-support spend as Roxi-AI's equity research reports and diligence sprints.

Emerging players

  • Consensus: AI research platform that surfaces cited answers from primary research for analysts and investors; comparable in model (AI copilot over research corpus) though it is not specialised to biopharma asset risk.

Broad incumbents

  • Certara: Provides quantitative biosimulation and R&D portfolio strategy software to pharma, with a broader scientific modelling portfolio that overlaps Roxi-AI's SIMULATOR scenario modelling for likelihood of success.
  • IQVIA: Large-scale R&D and commercial data, analytics and advisory franchise spanning clinical data, real-world evidence and trial analytics; a broad incumbent whose data assets and client base overlap Roxi-AI's biopharma risk intelligence market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

roxi-ai social profiles

Digital presence

roxi-ai financial estimates

Financial estimate

Revenue estimate

Valuation estimate

roxi-ai leadership team

Management profile

Number of profiles

Profiles2 records

roxi-ai funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

roxi-ai M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about roxi-ai

What does roxi-ai do?

Roxi-AI builds a longitudinal, outcomes-linked risk signals platform for biopharma: a knowledge graph that normalizes and time-stamps trial, regulatory, mechanistic, safety, competitive and commercial evidence, maps it to each asset's development path, and feeds explainable predictive models trained and validated against historical approvals, halts and regulatory guidance. The proprietary ROXI 100 framework codifies 900+ weighted, time-stamped risk signals linked to real outcomes, exposed through ROXI INDEX (AAA-D graded risk assessment), BENCHMARK PRO, SIMULATOR and the ASK ROXI AI research agent, and delivered as 72-hour diligence sprints, on-demand ticker/asset readouts, portfolio diagnostics, competitive/catalyst radar and advisory services.

Is roxi-ai a public or private company?

roxi-ai is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was roxi-ai founded?

roxi-ai was founded in 2024. It employs 1 to 10 people.

Where is roxi-ai based?

roxi-ai is headquartered in Yardley, United States, in the North America region.

How does roxi-ai make money?

Four revenue lines are on record. Platform/data subscription access are the primary driver. The others are diligence sprints and professional advisory services, ROXI CONNECT marketplace and outcome-linked risk data and benchmarking products.

Who are roxi-ai's main competitors?

Direct peers on record are Trilytics, Citeline, Evaluate Pharma, BioWorld, AlphaSense, DealForma and BioCentury. Consensus is listed as an emerging player. Broad incumbents are Certara and IQVIA.

Does roxi-ai have an API?

No public API is recorded for roxi-ai.

What industry is roxi-ai in?

roxi-ai's product category is Life Sciences Risk Intelligence Analytics. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGALAD, Risk Management & Benefit–Risk (RMP/REMS/PSUR-PBRER). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales